• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13D/A filed by Lifevantage Corporation (Amendment)

    11/14/23 3:19:27 PM ET
    $LFVN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $LFVN alert in real time by email
    SC 13D/A 1 sc13da213900002_11142023.htm AMENDMENT NO. 2 TO THE SCHEDULE 13D

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

    SCHEDULE 13D

    (Rule 13d-101)

    INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT

    TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO

    § 240.13d-2(a)

    (Amendment No. 2)1

    LifeVantage Corporation

    (Name of Issuer)

    Common Stock, par value $0.0001 per share

    (Title of Class of Securities)

    53222K205

    (CUSIP Number)

    Dayton Judd

    Sudbury Capital Fund, LP

    136 Oak Trail

    Coppell, Texas 75019

    (972) 304-5000

    (Name, Address and Telephone Number of Person

    Authorized to Receive Notices and Communications)

     

    November 10, 2023

    (Date of Event Which Requires Filing of This Statement)

     

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box ¨.

    Note:  Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits.  See § 240.13d-7 for other parties to whom copies are to be sent.

     

     

     

    1              The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

    CUSIP No. 53222K205

      1   NAME OF REPORTING PERSON  
             
            Sudbury Capital Fund, LP  
      2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☒
            (b) ☐
               
      3   SEC USE ONLY    
               
               
      4   SOURCE OF FUNDS  
             
            WC  
      5   CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) OR 2(e)     ☐
           
               
      6   CITIZENSHIP OR PLACE OF ORGANIZATION  
             
            Delaware  
    NUMBER OF   7   SOLE VOTING POWER  
    SHARES          
    BENEFICIALLY         - 0 -  
    OWNED BY   8   SHARED VOTING POWER  
    EACH          
    REPORTING         749,325  
    PERSON WITH   9   SOLE DISPOSITIVE POWER  
             
              - 0 -  
        10   SHARED DISPOSITIVE POWER  
               
              749,325  
      11   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
             
            749,325  
      12   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES     ☐
           
               
      13   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)  
             
            5.9%  
      14   TYPE OF REPORTING PERSON  
             
            PN  

      

    2

    CUSIP No. 53222K205

      1   NAME OF REPORTING PERSON  
             
            Sudbury Capital GP, LP  
      2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☒
            (b) ☐
               
      3   SEC USE ONLY    
               
               
      4   SOURCE OF FUNDS  
             
            AF  
      5   CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) OR 2(e)     ☐
           
               
      6   CITIZENSHIP OR PLACE OF ORGANIZATION  
             
            Texas  
    NUMBER OF   7   SOLE VOTING POWER  
    SHARES          
    BENEFICIALLY         - 0 -  
    OWNED BY   8   SHARED VOTING POWER  
    EACH          
    REPORTING         749,325  
    PERSON WITH   9   SOLE DISPOSITIVE POWER  
             
              - 0 -  
        10   SHARED DISPOSITIVE POWER  
               
              749,325  
      11   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
             
            749,325  
      12   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES     ☐
           
               
      13   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)  
             
            5.9%  
      14   TYPE OF REPORTING PERSON  
             
            PN  

      

    3

    CUSIP No. 53222K205

     

      1   NAME OF REPORTING PERSON  
             
            Sudbury Holdings, LLC  
      2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☒
            (b) ☐
               
      3   SEC USE ONLY    
               
               
      4   SOURCE OF FUNDS  
             
            AF  
      5   CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) OR 2(e)     ☐
           
               
      6   CITIZENSHIP OR PLACE OF ORGANIZATION  
             
            Texas  
    NUMBER OF   7   SOLE VOTING POWER  
    SHARES          
    BENEFICIALLY         - 0 -  
    OWNED BY   8   SHARED VOTING POWER  
    EACH          
    REPORTING         749,325  
    PERSON WITH   9   SOLE DISPOSITIVE POWER  
             
              - 0 -  
        10   SHARED DISPOSITIVE POWER  
               
              749,325  
      11   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
             
            749,325  
      12   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES     ☐
           
               
      13   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)  
             
            5.9%  
      14   TYPE OF REPORTING PERSON  
             
            OO, HC  

      

    4

    CUSIP No. 53222K205

     

      1   NAME OF REPORTING PERSON  
             
            Sudbury Capital Management, LLC  
      2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☒
            (b) ☐
               
      3   SEC USE ONLY    
               
               
      4   SOURCE OF FUNDS  
             
            AF  
      5   CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) OR 2(e)     ☐
           
               
      6   CITIZENSHIP OR PLACE OF ORGANIZATION  
             
            Texas  
    NUMBER OF   7   SOLE VOTING POWER  
    SHARES          
    BENEFICIALLY         - 0 -  
    OWNED BY   8   SHARED VOTING POWER  
    EACH          
    REPORTING         749,325  
    PERSON WITH   9   SOLE DISPOSITIVE POWER  
             
              - 0 -  
        10   SHARED DISPOSITIVE POWER  
               
              749,325  
      11   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
             
            749,325  
      12   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES     ☐
           
               
      13   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)  
             
            5.9%  
      14   TYPE OF REPORTING PERSON  
             
            OO, IA  

      

    5

    CUSIP No. 53222K205

     

      1   NAME OF REPORTING PERSON  
             
            Dayton Judd  
      2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☒
            (b) ☐
               
      3   SEC USE ONLY    
               
               
      4   SOURCE OF FUNDS  
             
            AF, PF  
      5   CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) OR 2(e)     ☐
           
               
      6   CITIZENSHIP OR PLACE OF ORGANIZATION  
             
            United States  
    NUMBER OF   7   SOLE VOTING POWER  
    SHARES          
    BENEFICIALLY         13,416  
    OWNED BY   8   SHARED VOTING POWER  
    EACH          
    REPORTING         749,325  
    PERSON WITH   9   SOLE DISPOSITIVE POWER  
             
              13,416  
        10   SHARED DISPOSITIVE POWER  
               
              749,325  
      11   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
             
            762,741  
      12   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES     ☐
           
               
      13   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)  
             
            6.0%  
      14   TYPE OF REPORTING PERSON  
             
            IN, HC  

      

    6

    CUSIP No. 53222K205

     

    The following constitutes Amendment No. 2 to the Schedule 13D filed by the undersigned (“Amendment No. 2”). This Amendment No. 2 amends the Schedule 13D as specifically set forth herein.

    Item 2.Identity and Background.

    Item 2 is hereby amended to add the following:

    As previously disclosed, on August 9, 2023, (i) the Reporting Persons, (ii) Bradley L. Radoff and The Radoff Family Foundation (collectively, “Radoff”) and (iii) Michael Lohner entered into a Joint Filing and Solicitation Agreement (the “Original Agreement”) for the purpose of, among other things, working together to enhance stockholder value at the Issuer, including by seeking representation on the Board of Directors of the Issuer at the fiscal year 2024 annual meeting of stockholders of the Issuer (the “Fiscal 2024 Annual Meeting”). Pursuant to its terms, the Original Agreement was scheduled to terminate upon the earlier to occur of the (i) certification of the results of the Fiscal 2024 Annual Meeting and (ii) written agreement of the Reporting Persons and Radoff. Prior to the certification of the results of the Fiscal 2024 Annual Meeting, the Reporting Persons and Radoff determined to continue to work together to enhance stockholder value and improve corporate governance at the Issuer. In connection therewith, on November 10, 2023, the Reporting Persons and Radoff entered into the Group Agreement (as defined and further described in Item 4). As a result, the Reporting Persons may continue to be deemed to be members of a “group,” within the meaning of Section 13(d)(3) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), comprised of the Reporting Persons and Radoff. It is the understanding of the Reporting Persons that Radoff will file a separate Schedule 13D with respect to its ownership of shares of Common Stock pursuant to Rule 13d-1(k)(2) of the Exchange Act. Reference is made to such Schedule 13D for information concerning Radoff and its investment in the Issuer.

    Item 3.Source and Amount of Funds or Other Consideration.

    Item 3 is hereby amended and restated to read as follows:

    The shares of Common Stock purchased by Sudbury Fund were purchased with working capital. The aggregate purchase price of the 749,325 shares of Common Stock directly owned by Sudbury Fund is approximately $3,840,357, including brokerage commissions.

    The shares of Common Stock owned by Mr. Judd were purchased with personal funds. The aggregate purchase price of the 13,416 shares of Common Stock directly owned by Mr. Judd is approximately $61,766, including brokerage commissions.

    Item 4.Purpose of Transaction.

    Item 4 is hereby amended to add the following:

    Prior to the certification of the results of the Fiscal 2024 Annual Meeting on November 10, 2023, the Reporting Persons and Radoff determined to continue to work together and in connection therewith entered into a group agreement (the “Group Agreement”) to supersede the Original Agreement for the purposes of working together to (i) enhance stockholder value and improve corporate governance at the Issuer, (ii) take all other action necessary to achieve the foregoing and (iii) take any other actions they determine to undertake in connection with their respective investment in the Issuer. The foregoing description of the Group Agreement does not purport to be complete and is subject to and is qualified in its entirety by reference to the full text of the Group Agreement, a copy of which is attached hereto as Exhibit 99.1 and is incorporated by reference herein.

    7

    CUSIP No. 53222K205

    On November 13, 2023, counsel to the Reporting Persons and Radoff delivered a letter to counsel to the Issuer (the “Document Preservation Notice”) notifying the Issuer of its obligations to take reasonable steps to preserve and retain all documents, including electronically stored information, in connection with the Reporting Persons and Radoff (i) exploring potential claims that the Issuer’s directors took steps to unlawfully entrench themselves in violation of their fiduciary duties to the Issuer’s stockholders, and (ii) investigating and potentially filing various claims regarding potential violations of securities laws by the Issuer, in particular Section 14(a) of the Exchange Act, in connection with the Fiscal 2024 Annual Meeting. The foregoing description of the Document Preservation Notice does not purport to be complete and is subject to and is qualified in its entirety by reference to the full text of the Document Preservation Notice, a copy of which is attached hereto as Exhibit 99.2 and is incorporated by reference herein.

    Item 5.Interest in Securities of the Issuer.

    Items 5(a) and (c) are hereby amended and restated to read as follows:

    (a)       The aggregate percentage of shares of Common Stock reported owned by each person named herein is based upon 12,713,887 shares of Common Stock outstanding as of November 8, 2023, which is the total number of shares of Common Stock outstanding as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 9, 2023.

    As of the date hereof, Sudbury Fund directly beneficially owned 749,325 shares of Common Stock, constituting approximately 5.9% of the outstanding shares.

    As of the date hereof, Mr. Judd directly beneficially owned 13,416 shares of Common Stock, constituting less than 1% of the outstanding shares.

    Sudbury GP, as the general partner of Sudbury Fund, may be deemed to beneficially own the 749,325 shares of Common Stock beneficially owned by Sudbury Fund, constituting approximately 5.9% of the outstanding shares. Sudbury Holdings, as the general partner of Sudbury GP, may be deemed to beneficially own the 749,325 shares of Common Stock beneficially owned by Sudbury Fund, constituting approximately 5.9% of the outstanding shares. Sudbury Management, as the investment adviser to Sudbury Fund, may be deemed to beneficially own the 749,325 shares of Common Stock beneficially owned by Sudbury Fund, constituting approximately 5.9% of the outstanding shares. Mr. Judd, as the Sole Member of Sudbury Holdings and Managing Member of Sudbury Management, may be deemed to beneficially own the 749,325 shares of Common Stock beneficially owned by Sudbury Fund, which, together with the 13,416 shares of Common Stock he beneficially owns directly, constitutes an aggregate of 762,741 shares of Common Stock, constituting approximately 6.0% of the outstanding shares.

    Radoff has represented to the Reporting Persons that it beneficially owns 861,250 shares of Common Stock. Collectively, Radoff and the Reporting Persons beneficially own 1,623,991 shares of Common Stock, which represents approximately 12.8% of the outstanding shares. Each Reporting Person disclaims beneficial ownership of the shares of Common Stock that he or it does not directly own. Furthermore, the Reporting Persons expressly disclaim beneficial ownership of the 861,250 shares of Common Stock beneficially owned by Radoff.

    (c)       There have been no transactions in securities of the Issuer by the Reporting Persons during the past 60 days.

    8

    CUSIP No. 53222K205

    Item 6.Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer.

    Item 6 is hereby amended to add the following:

    Prior to the certification of the results of the Fiscal 2024 Annual Meeting on November 10, 2023, the Reporting Persons and Radoff entered into the Group Agreement, as defined and described in Item 4 above and attached as Exhibit 99.1 hereto.

     

    Item 7.Material to be Filed as Exhibits.

    Item 7 is hereby amended to add the following exhibits:

     

    99.1Group Agreement, dated November 10, 2023.
    99.2Document Preservation Notice, dated November 13, 2023.

    9

    CUSIP No. 53222K205

     

    SIGNATURES

     

    After reasonable inquiry and to the best of his knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.

    Dated: November 14, 2023

      Sudbury Capital Fund, LP
       
      By: Sudbury Capital GP, LP
        General Partner
       
      By: Sudbury Holdings, LLC
        General Partner
         
      By:

    /s/ Dayton Judd

        Name: Dayton Judd
        Title: Sole Member

     

     

      Sudbury Capital GP, LP
       
      By: Sudbury Holdings, LLC
        General Partner
         
      By:

    /s/ Dayton Judd

        Name: Dayton Judd
        Title: Sole Member

     

     

      Sudbury Holdings, LLC
       
      By:

    /s/ Dayton Judd

        Name: Dayton Judd
        Title: Sole Member

     

     

      Sudbury Capital Management, LLC
       
      By:

    /s/ Dayton Judd

        Name: Dayton Judd
        Title: Managing Member

     

     

     

    /s/ Dayton Judd

      Dayton Judd

     

    10

     

    Get the next $LFVN alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $LFVN

    DatePrice TargetRatingAnalyst
    1/14/2025$35.00Buy
    Craig Hallum
    12/19/2024$26.00Buy
    Lake Street
    More analyst ratings

    $LFVN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Craig Hallum initiated coverage on Lifevantage with a new price target

      Craig Hallum initiated coverage of Lifevantage with a rating of Buy and set a new price target of $35.00

      1/14/25 8:36:52 AM ET
      $LFVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Lake Street initiated coverage on Lifevantage with a new price target

      Lake Street initiated coverage of Lifevantage with a rating of Buy and set a new price target of $26.00

      12/19/24 8:39:43 AM ET
      $LFVN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LFVN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Lewis Darwin bought $4,873 worth of shares (379 units at $12.86), increasing direct ownership by 0.33% to 116,767 units (SEC Form 4)

      4 - Lifevantage Corp (0000849146) (Issuer)

      6/17/25 4:11:27 PM ET
      $LFVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Mauro Garry Paul bought $26,338 worth of shares (2,150 units at $12.25), increasing direct ownership by 0.70% to 86,087 units (SEC Form 4)

      4 - Lifevantage Corp (0000849146) (Issuer)

      5/13/25 4:11:14 PM ET
      $LFVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Lewis Darwin bought $3,632 worth of shares (227 units at $16.00), increasing direct ownership by 0.20% to 116,388 units (SEC Form 4)

      4 - Lifevantage Corp (0000849146) (Issuer)

      12/17/24 5:00:17 PM ET
      $LFVN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LFVN
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • LifeVantage Declares Quarterly Dividend

      SALT LAKE CITY, May 06, 2025 (GLOBE NEWSWIRE) -- LifeVantage Corporation (NASDAQ:LFVN), a leading health and wellness company with products designed to activate optimal health processes at the cellular level, today announced that the Company's Board of Directors has approved a quarterly cash dividend of $0.045 per share of common stock, which will be paid June 13, 2025 to all stockholders of record at the close of business on May 30, 2025. This represents an increase in the dividend amount by 12.5% over the previous quarter. About LifeVantage Corporation LifeVantage Corporation (NASDAQ:LFVN), the Activation company, is a pioneer in nutrigenomics—the study of how nutrition and naturally o

      5/6/25 4:06:00 PM ET
      $LFVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • LifeVantage Announces Financial Results for the Third Quarter of Fiscal 2025

      SALT LAKE CITY, May 06, 2025 (GLOBE NEWSWIRE) -- LifeVantage Corporation (NASDAQ:LFVN), a leading health and wellness company with products designed to activate optimal health processes at the cellular level, today reported financial results for its third fiscal quarter ended March 31, 2025. Third Quarter Fiscal 2025 Summary*: Revenue was $58.4 million, an increase of 21.1% from the prior year period. Excluding the negative impact of foreign currency fluctuations, third quarter revenue increased approximately 22.1%;Revenue in the Americas increased 29.5%, and revenue in Asia/Pacific & Europe decreased 7.2%. Excluding the negative impact of foreign currency fluctuations, third quarter

      5/6/25 4:05:00 PM ET
      $LFVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Global Convention 2025 Empowers Consultants to 'Go Further' with Exclusive Trainings, Product Announcements, and New Incentives to Drive Growth

      SALT LAKE CITY, April 28, 2025 (GLOBE NEWSWIRE) -- LifeVantage Corporation® (NASDAQ:LFVN), a leading health and wellness company with products designed to activate optimal health processes at the cellular level, today announced the successful conclusion of their annual Global Convention, held April 24-26, 2025, in Salt Lake City, Utah. Thousands of independent LifeVantage Consultants from around the world gathered at the Salt Palace Convention Center to participate in the multi-day event. Attendees heard from a variety of LifeVantage executives and speakers on key business updates, exciting product announcements, exclusive business and compensation plan trainings, and initiatives designed

      4/28/25 8:00:00 AM ET
      $LFVN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LFVN
    SEC Filings

    See more
    • Lifevantage Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Lifevantage Corp (0000849146) (Filer)

      5/6/25 4:06:34 PM ET
      $LFVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Lifevantage Corporation

      10-Q - Lifevantage Corp (0000849146) (Filer)

      5/6/25 4:05:28 PM ET
      $LFVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Lifevantage Corporation

      10-Q - Lifevantage Corp (0000849146) (Filer)

      2/5/25 4:05:56 PM ET
      $LFVN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LFVN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Financial Officer Aure Carl converted options into 2,401 shares and sold $36,769 worth of shares (2,746 units at $13.39), decreasing direct ownership by 0.26% to 133,303 units (SEC Form 4)

      4 - Lifevantage Corp (0000849146) (Issuer)

      7/3/25 7:39:31 PM ET
      $LFVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • President and CEO Fife Steven R covered exercise/tax liability with 21,064 shares, decreasing direct ownership by 3% to 611,307 units (SEC Form 4)

      4 - Lifevantage Corp (0000849146) (Issuer)

      7/3/25 7:39:22 PM ET
      $LFVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • General Counsel Neufeld Alissa converted options into 2,667 shares and covered exercise/tax liability with 2,799 shares, decreasing direct ownership by 0.14% to 91,569 units (SEC Form 4)

      4 - Lifevantage Corp (0000849146) (Issuer)

      7/3/25 7:39:12 PM ET
      $LFVN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LFVN
    Leadership Updates

    Live Leadership Updates

    See more
    • LifeVantage Welcomes Todd Thompson as Chief Information and Innovation Officer

      SALT LAKE CITY, Jan. 16, 2025 (GLOBE NEWSWIRE) -- LifeVantage Corporation® (NASDAQ:LFVN), a leading health and wellness company with products designed to activate optimal health processes at the cellular level, is proud to announce the addition of Todd Thompson as Chief Information and Innovation Officer. Todd brings decades of experience driving transformative technology solutions and business growth for prominent global organizations. "We are thrilled to welcome Todd to the LifeVantage team," said Steve Fife, President and CEO of LifeVantage. "Todd's exceptional track record in technology leadership and his forward-thinking approach will be pivotal as we continue along our growth path

      1/16/25 8:00:00 AM ET
      $LFVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • LifeVantage Welcomes Rajendran Anbalagan to the Board of Directors; Thanks Erin Brockovich for Her Years of Service

      SALT LAKE CITY, Aug. 26, 2024 (GLOBE NEWSWIRE) -- LifeVantage Corporation (NASDAQ:LFVN), a leading health and wellness company with products designed to activate optimal health processes at the cellular level, announced the appointment of Rajendran Anbalagan to the Company's Board of Directors effective today. The appointment comes after the Board conducted a comprehensive search to identify a candidate with transformational digital skills and identified Mr. Anbalagan as an exceptional choice. "We are very excited to welcome Rajendran Anbalagan to the LifeVantage Board," said Ray Greer, Chairman. "Raj brings extensive technology experience along with a deep understanding of how to lever

      8/26/24 4:05:00 PM ET
      $LFVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • LifeVantage To Host "LifeVantage Open House" Virtual Calls on July 23 and 24

      SALT LAKE CITY, July 22, 2024 (GLOBE NEWSWIRE) -- LifeVantage Corporation (NASDAQ:LFVN), a leading health and wellness company with products designed to activate optimal health processes at the cellular level, will host Open House calls on July 23 and 24, for anyone wanting to learn more about LifeVantage, its activating products, and the Company's industry-leading compensation plan designed to meet modern sharers by supporting both product sellers and team builders. The Open House call on the 23rd will feature a Q&A with LifeVantage President and CEO, Steve Fife, Chief Sales Officer, Kristen Cunningham, and Regional Vice President of Sales, Jake Hines. The discussion will include the e

      7/22/24 6:27:51 PM ET
      $LFVN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LFVN
    Financials

    Live finance-specific insights

    See more
    • LifeVantage Declares Quarterly Dividend

      SALT LAKE CITY, May 06, 2025 (GLOBE NEWSWIRE) -- LifeVantage Corporation (NASDAQ:LFVN), a leading health and wellness company with products designed to activate optimal health processes at the cellular level, today announced that the Company's Board of Directors has approved a quarterly cash dividend of $0.045 per share of common stock, which will be paid June 13, 2025 to all stockholders of record at the close of business on May 30, 2025. This represents an increase in the dividend amount by 12.5% over the previous quarter. About LifeVantage Corporation LifeVantage Corporation (NASDAQ:LFVN), the Activation company, is a pioneer in nutrigenomics—the study of how nutrition and naturally o

      5/6/25 4:06:00 PM ET
      $LFVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • LifeVantage Announces Financial Results for the Third Quarter of Fiscal 2025

      SALT LAKE CITY, May 06, 2025 (GLOBE NEWSWIRE) -- LifeVantage Corporation (NASDAQ:LFVN), a leading health and wellness company with products designed to activate optimal health processes at the cellular level, today reported financial results for its third fiscal quarter ended March 31, 2025. Third Quarter Fiscal 2025 Summary*: Revenue was $58.4 million, an increase of 21.1% from the prior year period. Excluding the negative impact of foreign currency fluctuations, third quarter revenue increased approximately 22.1%;Revenue in the Americas increased 29.5%, and revenue in Asia/Pacific & Europe decreased 7.2%. Excluding the negative impact of foreign currency fluctuations, third quarter

      5/6/25 4:05:00 PM ET
      $LFVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • LifeVantage to Announce Third Quarter Fiscal Year 2025 Results on May 6, 2025

      SALT LAKE CITY, April 22, 2025 (GLOBE NEWSWIRE) -- LifeVantage Corporation (NASDAQ:LFVN) a leading health and wellness company with products designed to activate optimal health processes at the cellular level, today announced that it will release financial results for its third quarter ended March 31, 2025, after the stock market closes on Tuesday, May 6, 2025. The Company will hold a conference call for investors at 2:30 p.m. Mountain Time (4:30 p.m. Eastern Time) that same day. Investors interested in participating in the live call can dial (877) 704-4453 from the U.S. or international callers can dial (201) 389-0920. A telephone replay will be available approximately two hours after th

      4/22/25 4:05:00 PM ET
      $LFVN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LFVN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13D/A filed by Lifevantage Corporation

      SC 13D/A - Lifevantage Corp (0000849146) (Subject)

      7/31/24 8:07:09 PM ET
      $LFVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by Lifevantage Corporation (Amendment)

      SC 13D/A - Lifevantage Corp (0000849146) (Subject)

      2/15/24 4:29:36 PM ET
      $LFVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by Lifevantage Corporation (Amendment)

      SC 13D/A - Lifevantage Corp (0000849146) (Subject)

      2/15/24 4:27:16 PM ET
      $LFVN
      Biotechnology: Pharmaceutical Preparations
      Health Care